

Sélection des publications 2011 de l'équipe 1

Azzopardi N, Lecomte T, Ternant D, Boisdrion-Celle M, Piller F, Morel A, Gouilleux-Gruart V, Vignault-Desvignes C, Watier H, Gamelin E, Paintaud G.
Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.
Clin Cancer Res 2011, 17 : 6329-6337

Beresniak A, Gossec L, Goupille P, Saraux A, Bamberger M, Bregman B, Dupont D.
Direct cost-modeling of rheumatoid arthritis according to disease activity categories in France.
J Rheumatol 2011, 38 : 439-445

Borowiec AS, Hague F, Gouilleux-Gruart V, Lassoued K, Ouadid-Ahidouch H.
Regulation of IGF-1-dependent cyclin D1 and E expression by hEag1 channels in MCF-7 cells: The critical role of hEag1 channels in G1 phase progression.
Biochim Biophys Acta 2011, 1813 : 723-730

Cayla G, Hulot JS, O'Connor SA, Pathak A, Scott SA, Gruel Y, Silvain J, Vignalou JB, Huerre, de la Briolle A, Allanic F, Beygui F, Barthélémy O, Montalescot G, Collet JP.
Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis.
JAMA 2011, 306 : 1765-1774

Daguet A, Watier H.
2nd Charles Richet et Jules Héricourt Workshop: Therapeutic antibodies and anaphylaxis; May 31-June 1, 2011, Tours, France (Meeting report).
Mabs 2011, 3 : 417-421

Ducourau E, Mulleman D, Paintaud G, Chu Miow Lin D, Lauféron F, Ternant D, Watier H, Goupille P.
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases.
Arthritis Res Ther 2011, 13 : R105

Gaud G, Iochmann S, Guillon-Munos A, Brillet B, Petiot S, Seigneuret F, Touzé A, Heuzé-Vourc'h N, Courty Y, Lerondel S, Gruel Y, Reverdiau P.
TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions.
J Cell Mol Med 2011 15 : 196-208

Gruel Y, Watier H.
Bacteria and HIT: a close connection? (editorial)
Blood 2011, 117 : 1105-1106

Maillet A, Guilleminault L, Lemarié E, Lerondel S, Azzopardi N, Montharu J, Congy-Jolivet N, Reverdiau P, Legrain B, Parent C, Douvin DH, Hureaux J, Courty Y, De Monte M, Diot P, Paintaud G, Le Pape A, Watier H, Heuzé-Vourc'h N.
The airways, a novel route for delivering monoclonal antibodies to treat lung tumors.
Pharm Res 2011, 28 : 2147-2156

Mamessier E, Sylvain A, Thibault ML, Houvenaeghel G, Jacquemier J, Castellano R, Gonçalves A, André P, Romagné F, Thibault G, Viens P, Birnbaum D, Bertucci F, Moretta A, Olive D.
Human breast cancer cells enhance self-tolerance by promoting evasion from
NK cell antitumor immunity.
J Clin Invest 2011, 121 : 3609-3622

Méric JC, Mulleman D, Ducourau E, Lauféron F, Chu Miow Lin D, Watier H, Goupille P, Paintaud G.
Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study.
Ther Drug Monit 2011, 33 : 411-416

Mulleman D, Lauferon F, Wendling D, Ternant D, Ducourau E, Paintaud G, Goupille P.
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic
comparative study.
Arthritis Res Ther 2011, 13 : R82

N'Guessan K, Ternant D, Labarthe F, Watier H.
Lability of IgE levels early in life.
J Allergy (Cairo) 2011, 2011 : 547389

Passeron T, Goupille P, Boulinguez S.
[Recommendations on the management of psoriatic arthritis].
Ann Dermatol Venereol 2011, 138 (6 Suppl 1): H10-2

Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, Constantin A, Fautrel B, Gaudin P,
Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Huet I, Jullien D, Launay O, Lemann M,
Maillefert JF, Marolleau JP, Martinez V, Masson C, Morel J, Mouthon L, Pol S, Puéchal X, Richette P, Saraux A,
Schaevebeke T, Soubrier M, Sudre A, Tran TA, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibia J.
TNF alpha antagonist therapy and safety monitoring.
Joint Bone Spine 2011, 78 Suppl 1 : 15-185

Warkentin TE, Greinacher A, Gruel Y, Aster RH, Chong BH; on behalf of the scientific and standardization
committee of the international society on thrombosis and haemostasis.
Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for
diagnosis.
J Thromb Haemost 2011, 9 : 2498-2500

Wendling D, Prati C, Goupille P, Mulleman D.
Optimizing TNF α antagonist therapy in patients with spondyloarthritis : why and how?
Joint Bone Spine 2011, 78 : 225-227